New hope for young women with endometrial cancer: tailored treatments may save fertility

NCT ID NCT07319429

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to improve fertility-sparing treatment for young women (ages 18-45) with endometrial cancer by tailoring therapy to the tumor's genetic profile. Participants will receive either hormone therapy (progestins) or a combination with an immunotherapy drug (sintilimab), depending on their cancer subtype. The goal is to achieve complete cancer remission while preserving the uterus for future pregnancy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab (PD-1 antibody), medroxyprogesterone acetate, megestrol acetate
What this could lead to: If successful, this could offer more effective, personalized fertility-sparing options for young women with endometrial cancer, potentially increasing response rates and preserving the uterus.
What could go wrong: This is an early-phase trial with only 260 participants, so results may not apply to all patients. Some treatments carry risks like immune-related side effects, and not all molecular subtypes may respond as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER FERTILITY

Contacts and locations

Locations

Shanghai Tenth People's Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200090, China
Shanghai Tenth People's Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200090, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.